Long Acting Insulin Versus Multiple Dose Regimen for Control of Gestational Diabetes Mellitus
NCT ID: NCT04674332
Last Updated: 2021-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
148 participants
INTERVENTIONAL
2019-09-01
2020-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
NCT06178874
Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis
NCT05219942
Insulin for Hyperglycemia in Stroke Trial
NCT04834362
Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control
NCT05136157
Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation
NCT00779701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
long acting insulin
Long acting insulin
long acting insulin analogue once daily at bed time
multiple dose regimen
multiple dose regimen
intermediate and short acting insulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Long acting insulin
long acting insulin analogue once daily at bed time
multiple dose regimen
intermediate and short acting insulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* between 24-28 weeks gestation
Exclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
maii medhat nawara
associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Maternity Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
323/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.